Effect of pregnancy on emtricitabine pharmacokinetics

A. M. Stek, B. M. Best, W. Luo, E. Capparelli, S. Burchett, C. Hu, H. Li, J. S. Read, A. Jennings, E. Barr, E. Smith, S. S. Rossi, M. Mirochnick

Research output: Contribution to journalArticle

31 Scopus citations

Abstract

Objectives: The aim of the study was to describe emtricitabine pharmacokinetics during pregnancy and postpartum. Methods: The International Maternal Pediatric and Adolescent AIDS Clinical Trials (IMPAACT), formerly Pediatric AIDS Clinical Trials Group (PACTG), study P1026s is a prospective pharmacokinetic study of HIV-infected pregnant women taking antiretrovirals for clinical indications, including a cohort taking emtricitabine 200mg once daily. Intensive steady-state 24-hour emtricitabine pharmacokinetic profiles were performed during the third trimester and 6-12 weeks postpartum, and on maternal and umbilical cord blood samples collected at delivery. Emtricitabine was measured by liquid chromatography-mass spectrometry with a quantification limit of 0.0118mg/L. The target emtricitabine area under the concentration versus time curve, from time 0 to 24 hours post dose (AUC 0-24), was ≥7mgh/L (≤30% reduction from the typical AUC of 10mgh/L in nonpregnant historical controls). Third-trimester and postpartum pharmacokinetics were compared within subjects. Results: Twenty-six women had pharmacokinetics assessed during the third trimester (median 35 weeks of gestation) and 22 postpartum (median 8 weeks postpartum). Mean [90% confidence interval (CI)] emtricitabine pharmacokinetic parameters during the third trimester vs. postpartum were, respectively: AUC: 8.0 (7.1-8.9) vs. 9.7 (8.6-10.9) mgh/L (P=0.072); apparent clearance (CL/F): 25.0 (22.6-28.3) vs. 20.6 (18.4-23.2) L/h (P=0.025); 24 hour post dose concentration (C 24): 0.058 (0.037-0.063) vs. 0.085 (0.070-0.010) mg/L (P=0.006). The mean cord:maternal ratio was 1.2 (90% CI 1.0-1.5). The viral load was <400 HIV-1 RNA copies/mL in 24 of 26 women in the third trimester, in 24 of 26 at delivery, and in 15 of 19 postpartum. Within-subject comparisons demonstrated significantly higher CL/F and significantly lower C 24 during pregnancy; however, the C 24 was well above the inhibitory concentration 50%, or drug concentration that suppresses viral replication by half (IC 50) in all subjects. Conclusions: While we found higher emtricitabine CL/F and lower C 24 and AUC during pregnancy compared with postpartum, these changes were not sufficiently large to warrant dose adjustment during pregnancy. Umbilical cord blood concentrations were similar to maternal concentrations.

Original languageEnglish (US)
Pages (from-to)226-235
Number of pages10
JournalHIV Medicine
Volume13
Issue number4
DOIs
StatePublished - Apr 2012

Keywords

  • Emtricitabine
  • HIV
  • Pharmacokinetics
  • Pregnancy

ASJC Scopus subject areas

  • Health Policy
  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Effect of pregnancy on emtricitabine pharmacokinetics'. Together they form a unique fingerprint.

Cite this